CLINICAL TRIALS PROFILE FOR TOFACITINIB CITRATE
✉ Email this page to a colleague
All Clinical Trials for Tofacitinib Citrate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02197455 ↗ | Tofacitnib for the Treatment of Alopecia Areata and Variants | Completed | Yale University | Phase 2 | 2014-07-01 | The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants. |
| NCT02312882 ↗ | Tofacitinib for the Treatment of Alopecia Areata and Its Variants | Completed | Stanford University | N/A | 2014-12-01 | The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants. |
| NCT03002649 ↗ | Study of Tofacitinib in Refractory Dermatomyositis | Completed | Pfizer | Phase 1 | 2017-01-01 | The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatomyositis. |
| NCT03002649 ↗ | Study of Tofacitinib in Refractory Dermatomyositis | Completed | Johns Hopkins University | Phase 1 | 2017-01-01 | The purpose of this study is to obtain preliminary data regarding the safety and efficacy of Janus kinase (JAK) inhibitor, tofacitinib, in adults with active, treatment-refractory dermatomyositis. |
| NCT04114461 ↗ | Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers | Completed | Hanlim Pharm. Co., Ltd. | Phase 1 | 2019-11-06 | To evaluate the safety and pharmacokinetics of HL-TOF tab. 5 mg compared with those of XelJanz tab. in healthy volunteers |
| NCT04468425 ↗ | Tofacitinib Citrate Topical Gel 3.2% FDA BA Bridging Study | Recruiting | TWi Biotechnology, Inc. | Phase 1 | 2020-10-14 | This is a Phase 1, single center, open-label, fixed sequence, two-period pharmacokinetic (PK) study to evaluate the safety and relative systemic bioavailability of topical and oral tofacitinib formulations in approximately 14 healthy subjects. Participants will receive a single oral dose of tofacitinib 5 mg tablet in Period 1 of the study followed by a 7-day washout period. In Period 2, participants will receive repeat administration of Tofacitinib Citrate Topical Gel 3.2% BID for 14 days. |
| NCT05048238 ↗ | Tofacitinib in Prevention of Photosensitivity in Lupus | Not yet recruiting | Autoimmunity Centers of Excellence | Phase 1 | 2021-10-01 | This study will determine whether the treatment intervention, tofacitinib: - Impacts photosensitivity following ultraviolet light B (UVB) exposure in individuals with systemic lupus and a history of cutaneous disease - Is associated with changes in cutaneous disease activity in individuals with systemic lupus and a history of cutaneous disease after a 25-day regimen of tofacitinib - Is associated with changes in systemic lupus erythematosus (SLE) disease activity in individuals with systemic lupus and a history of cutaneous disease after a 25-day regimen of tofacitinib, and - Is well tolerated in individuals with systemic lupus and a history of cutaneous disease. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Tofacitinib Citrate
Condition Name
Clinical Trial Locations for Tofacitinib Citrate
Trials by Country
Clinical Trial Progress for Tofacitinib Citrate
Clinical Trial Phase
Clinical Trial Sponsors for Tofacitinib Citrate
Sponsor Name
